# Home-made anti-CD19 CAR-T cells for relapsed or refractory B-cell acute lymphoblastic leukaemia (Rawalpindi pilot)

Source: https://onco.cc/trials/nct07695012/  
OnCo record `nct07695012` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A small trial of CAR-T cells made in Pakistan: ten patients aged 5 to 50 with leukaemia that has come back or not responded, treated in Rawalpindi.

## Summary

Registered as early phase 1 on ClinicalTrials.gov (first posted 10 July 2026). Autologous T cells collected by leukapheresis at the Armed Forces Bone Marrow Transplant Centre are transduced with a self-inactivating third-generation lentiviral vector supplied by BIOCCUS (China), encoding an anti-CD19 single-chain variable fragment with a CD8-alpha hinge, a 4-1BB costimulatory domain and CD3-zeta, and expanded on an automated system. Eligible patients are aged 5 to 50 with relapsed or refractory B-cell acute lymphoblastic leukaemia. The primary outcome is the safety and feasibility of manufacturing and giving the product. Estimated enrolment is 10, with primary completion estimated for 31 December 2027, at the National University of Medical Sciences clinical trial unit in Rawalpindi. No results are posted.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Registry id: NCT07695012
- Phase: 1
- Setting: A Pilot, Single-Arm, Open-Label Feasibility Study of Autologous Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL)
- Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (sponsor-investigator Dr Zaineb Akram)
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT07695012: https://clinicaltrials.gov/study/NCT07695012

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Point-of-care and decentralised cell manufacturing](https://onco.cc/technologies/point-of-care-cell-manufacturing/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- institutions: [Armed Forces Bone Marrow Transplant Centre, Rawalpindi](https://onco.cc/institutions/afbmtc-rawalpindi/)
- terms: [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/)

---
JSON: https://onco.cc/api/v1/entities/nct07695012.json